Patients in this study were defined as T1DM and T2DM using clinical assessment at the time of initial evaluation as well as utilising a novel scoring system assessing; pre-transplant insulin requirement, pre-transplant fasting c-peptide levels (assigning a score of +2 if C-peptide <0.5 ng/L, −1 if 0.5–2 ng/L and −2 if >2 ng/L), family history and the presence of diabetes-associated antibodies. Here, INS is linked to type 2 diabetes mellitus.